| NCT ID | NCT05444452 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsung Medical Center |
| Condition | Ischemic Heart Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 850 participants |
| Start Date | 2022-04-24 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 850 participants in total. It began in 2022-04-24 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the efficacy and safety of abluminal biodegradable polymer ultrathin sirolimus-eluting stent (Genoss stent) as compared with a durable-polymer everolimus-eluting stent (Xience stent) in patients with coronary artery disease.
Eligibility Criteria
Inclusion Criteria: ① Subject must be at least 19 years of age ② Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily. ③ Patients with stable coronary artery disease or acute coronary syndrome and at least one lesion with greater than 50% diameter stenosis suitable for stent implantation Exclusion Criteria: * Pregnant women ② Patients unable to provide consent, ③ Patients with known intolerance to aspirin, clopidogrel, ticagrelor, prasugrel, heparin or components of drug-eluting stents (sirolimus or everolimus) * Patients who have non-cardiac co-morbid conditions with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
Contact & Investigator
Hyeon-Cheol Hyeon-Cheol, MD, PhD
PRINCIPAL INVESTIGATOR
Samsung Medical Center
Frequently Asked Questions
Who can join the NCT05444452 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Ischemic Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05444452 currently recruiting?
Yes, NCT05444452 is actively recruiting participants. Contact the research team at hcgwon@naver.com for enrollment information.
Where is the NCT05444452 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05444452 clinical trial?
NCT05444452 is sponsored by Samsung Medical Center. The principal investigator is Hyeon-Cheol Hyeon-Cheol, MD, PhD at Samsung Medical Center. The trial plans to enroll 850 participants.